Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells.
The book describes the effort undertaken by the author for developing some potential radiopharmaceuticals during the course of his Ph.D. work carried out at the Radiopharmaceuticals Division of Bhabha Atomic Research Centre, Mumbai, India. The book consists of four chapters. The first chapter briefly describes the different aspects related to radiopharmaceutical sciences. In the second chapter, development of three potential radiopharmaceuticals which could find use in liquid-filled balloons as IVRT agents has been described. Third chapter describes the development of two potential tumor-specific agents - one for the imaging of hypoxia tumors while the other one is for targeted tumor therapy. Last chapter deals with the development of two receptor-specific agents - one has the potential for imaging tumors over-expressing androgen receptors while the other for targeted therapy of tumors which over-express estrogen receptors. This chapter also describes the excellent potential of 177Lu, which may become one of the most important therapeutic radionuclide in the near future.